Literature DB >> 22496497

The impact of age and gender on papillary thyroid cancer survival.

J Jonklaas1, G Nogueras-Gonzalez, M Munsell, D Litofsky, K B Ain, S T Bigos, J D Brierley, D S Cooper, B R Haugen, P W Ladenson, J Magner, J Robbins, D S Ross, M C Skarulis, D L Steward, H R Maxon, S I Sherman.   

Abstract

CONTEXT: Thyroid cancer predominately affects women, carries a worse prognosis in older age, and may have higher mortality in men. Superimposed on these observations is the fact that most women have attained menopause by age 55 yr.
OBJECTIVE: The objective of the study was to determine whether men contribute disproportionately to papillary thyroid cancer (PTC) mortality or whether menopause affects PTC prognosis.
DESIGN: Gender-specific mortality was normalized using age-matched subjects from the U.S. population. Multivariate Cox proportional hazard regression models incorporating gender, age, and National Thyroid Cancer Treatment Cooperative Study Group stage were used to model disease-specific survival (DSS). PARTICIPANTS AND
SETTING: Patients were followed in a prospective registry. MAIN OUTCOME MEASURE: The relationships between gender, age, and PTC outcomes were analyzed.
RESULTS: The unadjusted hazard ratio (HR) for DSS for women was 0.40 [confidence interval (CI) 0.24-0.65]. This female advantage diminished when DSS was adjusted for age at diagnosis and stage with a HR encompassing unity (HR 0.72, CI 0.44-1.19). Additional multivariate models of DSS considering gender, disease stage, and various age groupings showed that the DSS for women diagnosed at under 55 yr was improved over men (HR 0.33, CI 0.13-0.81). However, the HR for DSS increased to become similar to men for women diagnosed at 55-69 yr (HR 1.01, CI 0.42-2.37) and at 70 yr or greater (HR 1.17, CI 0.48-2.85).
CONCLUSIONS: Although the overall outcome of women with PTC is similar to men, subgroup analysis showed that this composite outcome is composed of two periods with different outcomes. The first period is a period with better outcomes for women than men when the diagnosis occurs at younger than 55 yr; the second is a period with similar outcomes for both women and men diagnosed at ages greater than 55 yr. These data raise the question of whether an older age cutoff would improve current staging systems. We hypothesize that older age modifies the effect of gender on outcomes due to menopause-associated hormonal alterations.

Entities:  

Mesh:

Year:  2012        PMID: 22496497      PMCID: PMC3387425          DOI: 10.1210/jc.2011-2864

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  60 in total

1.  Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question.

Authors:  Rossella Elisei; Eleonora Molinaro; Laura Agate; Valeria Bottici; Lucio Masserini; Claudia Ceccarelli; Francesco Lippi; Lucia Grasso; Fulvio Basolo; Generoso Bevilacqua; Paolo Miccoli; Giancarlo Di Coscio; Paolo Vitti; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

Review 2.  Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer.

Authors:  George G Chen; Alexander C Vlantis; Qiang Zeng; C Andrew van Hasselt
Journal:  Curr Cancer Drug Targets       Date:  2008-08       Impact factor: 3.428

3.  Improving rates for screening colonoscopy: Analysis of the health information national trends survey (HINTS I) data.

Authors:  Timothy M Geiger; Brent W Miedema; Mugur V Geana; Klaus Thaler; Nitin J Rangnekar; Glen T Cameron
Journal:  Surg Endosc       Date:  2007-12-11       Impact factor: 4.584

4.  Toward understanding nonparticipation in sigmoidoscopy screening for colorectal cancer.

Authors:  Johannes Blom; Li Yin; Annika Lidén; Anders Dolk; Bengt Jeppsson; Lars Påhlman; Lars Holmberg; Olof Nyrén
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

5.  The advantage of women in cancer survival: an analysis of EUROCARE-4 data.

Authors:  A Micheli; R Ciampichini; W Oberaigner; L Ciccolallo; E de Vries; I Izarzugaza; P Zambon; G Gatta; R De Angelis
Journal:  Eur J Cancer       Date:  2008-12-26       Impact factor: 9.162

6.  Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy.

Authors:  Guia Vannucchi; Michela Perrino; Stefania Rossi; Carla Colombo; Leonardo Vicentini; Davide Dazzi; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  Eur J Endocrinol       Date:  2009-10-14       Impact factor: 6.664

7.  Metastatic phenotype is regulated by estrogen in thyroid cells.

Authors:  Shilpi Rajoria; Robert Suriano; Arulkumaran Shanmugam; Yushan Lisa Wilson; Stimson P Schantz; Jan Geliebter; Raj K Tiwari
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

8.  The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival.

Authors:  Stephen F Sener; David J Winchester; David P Winchester; Hongyan Du; Ermilo Barrera; Malcolm Bilimoria; Seth Krantz; Sarah Rabbitt
Journal:  Am J Surg       Date:  2009-03       Impact factor: 2.565

9.  Papillary thyroid carcinoma: factors influencing recurrence and survival.

Authors:  Antonio Toniato; Isabella Boschin; Dario Casara; Renzo Mazzarotto; Domenico Rubello; Mariarosa Pelizzo
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

10.  Long-term results and prognostic factors in patients with differentiated thyroid carcinoma.

Authors:  M Tubiana; M Schlumberger; P Rougier; A Laplanche; E Benhamou; P Gardet; B Caillou; J P Travagli; C Parmentier
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

View more
  74 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.

Authors:  Jia-Li Jiang; Gui-Lan Tian; Shu-Jiao Chen; L I Xu; Hui-Qin Wang
Journal:  Exp Ther Med       Date:  2015-07-24       Impact factor: 2.447

3.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

4.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Laura Y Wang; Jocelyn C Migliacci; Antoine Eskander; Michael J Campbell; Ahmad Aniss; Lilah Morris; Fernanda Vaisman; Rossana Corbo; Denise Momesso; Mario Vaisman; Andre Carvalho; Diana Learoyd; William D Leslie; Richard W Nason; Deborah Kuk; Volkert Wreesmann; Luc Morris; Frank L Palmer; Ian Ganly; Snehal G Patel; Bhuvanesh Singh; R Michael Tuttle; Ashok R Shaha; Mithat Gönen; K Alok Pathak; Wen T Shen; Mark Sywak; Luis Kowalski; Jeremy Freeman; Nancy Perrier; Jatin P Shah
Journal:  Thyroid       Date:  2016-02-25       Impact factor: 6.568

5.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

6.  Establishment and validation of a nomogram model for predicting the survival probability of differentiated thyroid carcinoma patients: a comparison with the eighth edition AJCC cancer staging system.

Authors:  Ruyi Zhang; Mei Xu; Xiangxiang Liu; Miao Wang; Qiang Jia; Shen Wang; Xiangqian Zheng; Xianghui He; Chao Huang; Yaguang Fan; Heng Wu; Ke Xu; Dihua Li; Zhaowei Meng
Journal:  Endocrine       Date:  2021-04-06       Impact factor: 3.633

Review 7.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

8.  Age-based disparities in the use of total thyroidectomy for papillary thyroid carcinoma.

Authors:  I V Shevchyk; B A Cobian; S R Martinez
Journal:  Clin Transl Oncol       Date:  2017-04-24       Impact factor: 3.405

9.  BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Authors:  Fei Wang; Shihua Zhao; Xiaopei Shen; Guangwu Zhu; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Mingzhao Xing
Journal:  J Clin Oncol       Date:  2018-08-02       Impact factor: 44.544

10.  30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.

Authors:  Yingqiang Zhang; Chen Wang; Xin Zhang; Hui Li; Xin Li; Yansong Lin
Journal:  Endocrine       Date:  2018-08-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.